足细胞病中血尿的意义
本研究在Nephrotic Syndrome Study Network和Cure Glomerulonephropathy队列中评估了膜性肾病、微小病变和FSGS患者初始尿检血尿的患病率及其与肾脏结局的关联。结果显示33%的患者存在血尿,血尿与复合终点风险升高(HR 1.31)及蛋白尿缓解率降低(HR 0.80)独立相关。
要点
- 在三种足细胞病中,33%的患者初始尿检血尿阳性。
- 血尿与复合终点(肾衰竭或eGFR下降40%且eGFR<60)风险升高独立相关(HR 1.31)。
- 血尿与蛋白尿缓解(UPCR<0.3 mg/mg)率降低独立相关(HR 0.80)。
核心结论
- 血尿在三种足细胞病中普遍存在,且与更差的肾脏相关结局(包括肾功能进行性丧失和蛋白尿缓解)显著且独立相关。
研究设计与样本
- 基于Nephrotic Syndrome Study Network和Cure Glomerulonephropathy队列,纳入随访>24个月的膜性肾病、微小病变和FSGS的成人和儿童患者,共1516例。
主要发现
- 528例(35%)为FSGS,499例(33%)为微小病变,489例(32%)为膜性肾病;从肾活检至研究初始尿检的中位时间(IQR)为260(49-750)天,498例(33%)血尿阳性。
- 血尿阳性者较阴性者年龄更大(37 [16-55]岁 vs 33 [12-55]岁),更可能诊断为膜性肾病(44% vs 27%),肾活检后时间更短(139 [27-477]天 vs 325 [89-878]天),UPCR更高(3.8 [1.4-8.0] g/g vs 0.9 [0.1-3.1] g/g)。
- 调整诊断、年龄、性别、UPCR、eGFR、肾活检后时间和研究队列后,血尿与复合终点风险升高相关(HR 1.31;95% CI 1.04-1.65;P=0.02),与蛋白尿缓解率降低相关(HR 0.80;95% CI 0.65-0.98;P=0.03)。
临床怎么用
- 在足细胞病患者的初始评估中,应关注尿检血尿的存在,其与更差的肾脏相关结局独立相关。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hematuria is frequently present in podocytopathies, but its significance and prognostic value is not well described in these proteinuric kidney diseases. This study describes the prevalence and association between hematuria and kidney-related outcomes in these disorders. METHODS: Hematuria was assessed at the initial urinalysis in participants with the following podocytopathies-membranous nephropathy, minimal change disease, and FSGS-in the Nephrotic Syndrome Study Network and Cure Glomerulonephropathy cohorts with >24 months of follow-up. Multivariable Cox proportional hazards models were fit for time to composite outcome (kidney failure or 40% decline in eGFR and eGFR <60 ml/min per 1.73 m 2 ) and proteinuria remission (urine protein-to-creatinine ratio [UPCR] <0.3 mg/mg). RESULTS: Among the 1516 adults and children in the study, 528 participants (35%) had FSGS, 499 (33%) had minimal change disease, and 489 (32%) had membranous nephropathy. Median (interquartile range) time from biopsy until the initial study urinalysis was 260 (49-750) days, and 498 participants (33%) were positive for hematuria. Participants with hematuria compared with those without were older (37 [16-55] versus 33 [12-55] years), more likely to have an underlying diagnosis of membranous nephropathy (44% versus 27%), had shorter time since biopsy (139 [27-477] versus 325 [89-878] days), and had higher UPCR (3.8 [1.4-8.0] versus 0.9 [0.1-3.1] g/g). After adjusting for diagnosis, age, sex, UPCR, eGFR, time since biopsy, and study cohort, hematuria was associated with a higher risk of reaching the composite outcome (hazard ratio, 1.31; 95% confidence interval, 1.04 to 1.65; P value, 0.02) and lower rate of reaching proteinuria remission (hazard ratio, 0.80; 95% confidence interval, 0.65 to 0.98; P value, 0.03). CONCLUSIONS: Hematuria is prevalent among participants with the three podocytopathies and is significantly and independently associated with worse kidney-related outcomes, including both progressive loss of kidney function and remission of proteinuria.
引用
- Marchel D, Trachtman H, Larkina M, et al. The Significance of Hematuria in Podocytopathies. Clin J Am Soc Nephrol. 2023. PMID: 37733352. doi:10.2215/CJN.0000000000000309
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。